The Latest Articles from Streetwise Reports


5 Small-Caps on Fund Manager Steve Palmer's Radar Screen

  ()
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. read more >
News Update

Cannabis Firm Announces Brand for Recreational Aficionados

News Update
  ()
This Canadian company intends to next launch a marketing campaign for the new product suite. read more >

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

Research Report
  ()
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. read more >
News Update

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference

News Update
  ()
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. read more >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial

Research Report
  ()
A Ladenburg Thalmann report reviewed the study design and purpose. read more >

Disruptive Delivery Company Signs Deal for Cannabis Distribution

Contributed Opinion
  ()
Technical analyst Clive Maund discusses both the fundamentals and technicals for this company that just signed a cannabis distribution agreement with a Vancouver-based retailer. read more >
News Update

Logistics Firm Moves Further Toward Becoming 'Uber of Cannabis for Canada'

News Update
  ()
This company forges partnerships with cannabis companies to deliver, within an hour, their products to customers. read more >
News Update

Tech Firm Launches Augmented Reality Showcase for Legal Cannabis Products

News Update
  ()
The new platform promises to provide a unique e-commerce experience in the legal cannabis industry, combining customer education and support for online transactions. read more >

Marijuana: Up in Smoke

Contributed Opinion
  ()
Sector expert Ron Struthers takes a look at a spectrum of cannabis companies, including one company that's gone from a high to a downer, a sector leader, and a firm that promotes CBDs as good for sex. read more >

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

Research Report
  ()
This California company expects results from clinical trials in liver disease and psoriasis in 2019. read more >

Large US Market Now Open to Livestock Feed Antibiotic Replacement

  ()
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. read more >

Coverage Initiated on Cancer Vaccine Firm

Research Report
  ()
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. read more >

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

Research Report
  ()
A ROTH Capital Partners report presented the reasons for investing in this company. read more >
News Update

Augmented Reality and Healthcare Tech Firms to Collaborate

News Update
  ()
The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >
News Update

Firm Launches App to Help Physicians Provide Virtual Counseling

News Update
  ()
This new initiative combines emerging technologies and human skill-based expertise. read more >

After Financing Close, Biotech's Subsidiary to Operate Independently

Research Report
  ()
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. read more >

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types

Research Report
  ()
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. read more >

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

Research Report
  ()
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. read more >
News Update

Livestock Feed Developer Partners to Initiate Product Sales in the U.S.

News Update
  ()
The arrangement represents this Canadian life sciences firm's entrée into a significant market. read more >

Biopharma's Foundation Provides for Downside Protection, Upside Realization

Research Report
  ()
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. read more >
News Update

Canadian Company Completes Two Cannabis Harvests

News Update
  ()
The firm also makes progress in obtaining technology rights and various licenses. read more >
News Update

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease

News Update
  ()
The Canadian company continues seeking partners to leverage its discovery and development platform. read more >

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise'

Research Report
  ()
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report. read more >

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases

Research Report
  ()
Analyst expects "transformational year" for company with a phase 3 trial underway. read more >
Showing Results: 1 to 25 of 105 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX plans to respond to a complete response letter for Posimir." ❭
– Patrick Dolezal, LifeSci Capital
"VIV signed a partnership with CSA Animal Nutrition." ❭
– Alex Koyfman, First Call
"We expect PMN to forge a licensing deal in Q2/19 or Q3/19." ❭
– André Uddin, Mackie Research Capital